Summary
Carbamazepine (2.7–3 mg/kg) was administered orally as an alcoholic solution (50% v/v) to eight healthy volunteers. Two of the subjects were also given 50 mg and 100 mg of carbamazepine in alcoholic solution and 200 mg as a tablet. Plasma concentrations, which were analysed by mass fragmentography, reached a maximum 1 – 7 hours after dosing, and then declined monoexponentially with half-lives ranging from 24 to 46 hours. The half-lives were independent of dose. The apparent distribution volume ranged from 0.79 to 1.40 l/kg. It was found that 72% of carbamazepine was bound to plasma proteins with little interindividual variation, and this was not influenced by the presence of diphenylhydantoin or phenobarbital in therapeutic concentrations. The pharmacokinetic parameters calculated from single oral doses were used to predict the steady-state plasma concentration expected after treatment with multiple doses of 200 mg three times daily. The predicted steady-state concentration was 2 – 3 times higher than that reported in patients undergoing chronic treatment with carbamazepine at this dose level, i.e. the pharmacokinetics of carbamazepine apparently change during multiple dosing.
Similar content being viewed by others
References
Alexandersson, B.: On interindividual variability in plasma levels of nortriptyline and desmethyl-imipramine in man: A pharmacokinetic and genetic study. Linköping University Medical Dissertations No 6 (1972)
Boyes, R.N., Scott, D.B., Jebson, P.J., Goodman, M.J., Julian, D.G.: Pharmacokinetics of lidocaine in man. Clin. Pharmacol. Ther.12 105–116 (1971)
Breckenridge, A., Rosén, A.: The binding of chlorothiazide to plasma proteins. Biochem. biophys. Acta229 610–617 (1971)
Cereghino, J.J., Van Meter, J.C., Brokc, J.J., Penry, J.K. Smith, L.D., White, B.G.: Preliminary observations of serum carbamazepine concentration in epileptic patients. Neurology (Minneap.)23 357–365 (1973)
Dollery, C.I., Ehmslie-Smith, D., Muggleton, D.F.: Actions of chlorothiazide in hypertension. Proc. roy. Soc. Med.53 592–594 (1960)
Evans, G.H., Nies, A.S., Shand, D.G.: The disposition of propranolol III. Decreased half life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J. Pharmacol. exp. Ther.186 114–122 (1973)
Frey, H., Yrjänä, T.: Carbamazepine titers of epileptic patients. Scand. J. clin. Lab. Invest. Suppl.113 90 (1970)
Hansen, J., Siersbaek-Nielsen, K., Skovsted, L.: Carbamazepine — induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin. Pharmacol. Ther.12 539–543 (1971)
Livingstone, S., Villmater, C., Sahata, Y., and Pauli, L.: Use of carbamazepine in epilepsy. Result in 87 patients. J. Amer. med. Ass.200 204–208 (1967)
Lunde, P.K.M., Rane, A., Yaffe, S.J., Lund, L., Sjöqvist, F.: Plasma protein binding of diphenylhydantoin in man. Clin. Pharmacol. Ther.11 846–855 (1970)
Meinardi, H.:In: Antiepileptic drugs, pp 487–496 (ed. Woodbury, D.M., Penry, J.K., Scmidt, R.P.) New York: Raven Press 1972
Palmér, L., Bertilsson, L., Collste, P., Rawlins, M.: Quantitative determination of carbamazepine in plasma by mass fragmentography. Clin. Pharmacol. Ther.14 827–832 (1973)
Rasmussen, P., Riishede, J.: Facial pain treated with carbamazepine. Acta neurol. scand.46 385–408 (1970)
Wagner, J.G., Northam, J.I., Alway, C.D., Carpenter, O.S.: Blood levels of drug at the equilibrium state after multiple dosing. Nature207 1301–1302 (1965)
Wagner, J.G.:In: Biopharmaceutics and relevant pharmacokinetics. Hamilton, Illinois: Drug Intelligence Publications, 1971
Author information
Authors and Affiliations
Additional information
Dedicated to the memory of Balzar Alexandersson, MD.
Medical Research Council (U.K.) Travelling Fellow
Rights and permissions
About this article
Cite this article
Rawlins, M.D., Collste, P., Bertilsson, L. et al. Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol 8, 91–96 (1975). https://doi.org/10.1007/BF00561556
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561556